TrialRespiratory research2022

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.

Elisabeth De Leeuw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.